**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 62761

**Manuscript Type:** LETTER TO THE EDITOR

**Is there higher percentage of undetected osteopenia and osteoporosis among patients with ulcerative colitis in Saudi Arabia?**

Olic Akrapovic I *et al*. Osteopenia/osteoporosis among ulcerative colitis patients

Ivna Olic Akrapovic, Mislav Radic, Ante Tonkic

**Ivna Olic Akrapovic,** Intensive Care Unit of the Department of Internal Medicine, University Hospital Centre Split, Split 21000, Croatia

**Mislav Radic,** Division of Rheumatology and Clinical Immunology, Centre of Excellence for Systemic Sclerosis Ministry of Health Republic of Croatia, University Hospital Centre Split, Split 21000, Croatia

**Mislav Radic, Ante Tonkic,** School of Medicine, University of Split, Split 21000, Croatia

**Ante Tonkic,** Department of Gastroenterology and Hepatology, University Hospital Centre Split, Split 21000, Croatia

**Author contributions:** Akrapovic Olic I and Radic M designed research; Akrapovic Olic I performed research; Akrapovic Olic I and Radic M analyzed data; Akrapovic Olic I wrote the letter; Radic M and Tonkic A revised the letter.

**Corresponding author: Mislav Radic, PhD, Assistant Professor,** Division of Rheumatology and Clinical Immunology, Centre of Excellence for Systemic Sclerosis Ministry of Health Republic of Croatia, University Hospital Centre Split, Soltanska 1, Split 21000, Croatia. mislavradic@gmail.com

**Received:** January 17, 2021

**Revised:** March 29, 2021

**Accepted:** June 25, 2021

**Published online:**

**Abstract**

Detection of prevalence and development of osteopenia or osteoporosis in patients with inflammatory bowel disease using only bone mineral density could be inappropriate to detect all individuals at risk for osteoporosis. Numerous patients could remain undetected by using only bone mineral density as a screening method, especially in patients with ulcerative colitis. Therefore, trabecular bone score should be used as a complementary method.

**Key Words:** Inflammatory bowel disease; Osteoporosis; Bone mineral density; Trabecular bone score

Olic Akrapovic I, Radic M, Tonkic A. Is there higher percentage of undetected osteopenia and osteoporosis among patients with ulcerative colitis in Saudi Arabia? *World J Gastroenterol* 2021; In press

**Core Tip:** Lower body mass index is a predictor of osteoporosis in patients with inflammatory bowel disease however, fracture risk can be increased desite normal bone mineral density. Therefore, use of trabecular bone score would ensure recruitment of individuals with normal bone mineral density at increased risk of fractures in trials.

**TO THE EDITOR**

We read with a great interest the study by Ewid *et al*[1], that evaluated the connection between inflammatory bowel disease (IBD) and bone mineral density (BMD) in a sample of adult Saudi patients with IBD from a single center.

One important finding of this study was that  Crohn’s disease (CD) patients are at a higher risk of developing both osteoporosis and osteopenia than ulcerative colitis (UC) patients, even though the study included more patients with severe clinical disease activity and endoscopic activity in the UC group than in the CD group (25% *vs* 5%, respectively). In spite of disease severity, 78% of UC patients had normal BMD *vs* 44% of CD patients. Fracture risk can be increased despite normal BMD. Maldonado *et al*[2] suggested that current screening does not include all IBD patients at increased risk of fractures. We propose using trabecular bone score (TBS) as a complementary tool; as it discriminates patients at higher risk of fractures better than BMD[3].

According to demographic characteristics in the study, mesalamine use was significantly higher in the UC compared to CD group (81% *vs* 10%, respectively). Due to the sample size of UC group an analysis of BMD according to mesalamine use probably could not have been performed nevertheless, the analysis would be highly informative. Hence, we postulate a question: could mesalamine use have contributed to lower risk of developing osteoporosis in UC compared to the CD cohort?

Krajcovicova *et al*[4] observed no significant difference in the prevalence of low BMD in groups of patients with UC and CD. They observed that corticosteroid therapy and menopause had significant negative effects, whereas combined treatment with an anti-tumor necrosis factor (TNF) α agent and azathioprine had a significant positive effect on Δ BMD at the lumbar spine (BMDL) per year[4].

The study also showed that low BMI is a risk factor for reduced BMD. According to Fawzy *et al*[5] and Steinschneider *et al*[6], increased BMD commonly reported in overweight women may be a result of soft tissue interference, further supporting addition of TBS as a screening method for osteoporosis in research and  clinical practice.

An unexpected finding in this study is the lack of correlation between steroid use and BMD. Paggiosi *et al*[7] demonstrated that TBS alone and BMDL in combination with TBS, but not BMDL alone were able to discriminate between glucocorticoid-treated and glucocorticoid-naïve women. In the study by Gulyás *et al*[8] TNF-α inhibition slowed down generalized bone loss in rheumatoid arthritis and ankylosing spondylitis. Effect of anti TNF therapy on bone metabolism was not confirmed by Ewid *et al*[1] hence, the effect is questionable in IBD.

Addition of TBS would enable inclusion of individuals with normal BMD at increased fracture risk. In conclusion, by including both screening methods osteoporotic fracture risk in UC *vs* CD cohort could be assessed more accurately.

**REFERENCES**

1 **Ewid M**, Al Mutiri N, Al Omar K, Shamsan AN, Rathore AA, Saquib N, Salaas A, Al Sarraj O, Nasri Y, Attal A, Tawfiq A, Sherif H. Updated bone mineral density status in Saudi patients with inflammatory bowel disease. *World J Gastroenterol* 2020; **26**: 5343-5353 [PMID: 32994692 DOI: 10.3748/wjg.v26.i35.5343]

2 **Maldonado FJ**, Al Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. *Inflamm Bowel Dis* 2019; **25**: 1072-1079 [PMID: 30476314 DOI: 10.1093/ibd/izy341]

3 **McCloskey EV**, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJM, Fujita Y, Glüer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren Ö, Lorentzon M, Mellström D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. *J Bone Miner Res* 2016; **31**: 940-948 [PMID: 26498132 DOI: 10.1002/jbmr.2734]

4 **Krajcovicova A**, Hlavaty T, Killinger Z, Miznerova E, Toth J, Letkovsky J, Nevidanska M, Cierny D, Koller T, Zelinkova Z, Huorka M, Payer J. Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients. *J Crohns Colitis* 2014; **8**: 1693-1701 [PMID: 25175812 DOI: 10.1016/j.crohns.2014.08.004]

5 **Fawzy T**, Muttappallymyalil J, Sreedharan J, Ahmed A, Alshamsi SO, Al Ali MS, Al Balsooshi KA. Association between Body Mass Index and Bone Mineral Density in Patients Referred for Dual-Energy X-Ray Absorptiometry Scan in Ajman, UAE. *J Osteoporos* 2011; **2011**: 876309 [PMID: 21772978 DOI: 10.4061/2011/876309]

6 **Steinschneider M**, Hagag P, Rapoport MJ, Weiss M. Discordant effect of body mass index on bone mineral density and speed of sound. *BMC Musculoskelet Disord* 2003; **4**: 15 [PMID: 12864923 DOI: 10.1186/1471-2474-4-15]

7 **Paggiosi MA**, Peel NF, Eastell R. The impact of glucocorticoid therapy on trabecular bone score in older women. *Osteoporos Int* 2015; **26**: 1773-1780 [PMID: 25743176 DOI: 10.1007/s00198-015-3078-1]

8 **Gulyás K**, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhász B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szücs G, Szekanecz Z, Szamosi S, Szántó S. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. *Clin Rheumatol* 2020; **39**: 167-175 [PMID: 31522318 DOI: 10.1007/s10067-019-04771-3]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 17, 2021

**First decision:** February 23, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Croatia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Huan C, Kamimura K, Takagi T, Wakao H **S-Editor:** Liu M **L-Editor: P-Editor:**